My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes : Episode 6

Opinion

Video

July 9, 2024

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

Now Viewing

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following question:

In which patients might you consider first-line doublet therapy (venetoclax + BTK inhibitor)?

Related Content

November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine

April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

November 13th 2024

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center

November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com

November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL